ExAdEx-Innov
- Company typePrivate
- Founded2022
- HeadquartersNice, France
- Headcount1–10
- GTM typeB2B
- OfferingServices
ExAdEx-Innov firmographics
Firmographics- Name
- ExAdEx-Innov
- Legal name
- ExAdEx-Innov
- Website
- https://exadex-innov.com
- Company type
- Private
- Founded year
- 2022
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
ExAdEx-Innov industry classification
Industry- Product category
- Preclinical Biotechnology Research Services
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Organoids & Organ-on-Chip (regenerative models) (HLAAAGAD)
- akta.pro secondary industries
- In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems) (HLAAAIAJ), Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)
Keywords
Where ExAdEx-Innov is headquartered
LocationHeadquarters
- HQ city
- Nice
- HQ country
- France
- HQ region
- Europe
Offices2 records
Markets served
ExAdEx-Innov business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- R&D Services and Testing: Provides assay and analytical services to pharmaceutical, cosmetic, and nutraceutical companies. Offers multi-parametric testing across molecular, functional, and metabolic activity assays using their ex vivo tissue models. Services include custom study design, tissue sourcing, and comprehensive analysis packages.
- Technology Licensing: Licenses proprietary ExAdEx technology and patented tissue models to partners for specific applications. Includes license agreements for technology platforms (e.g., hMADS cells from CNRS Innovation).
- Collaborative Research/Co-development: Joint development projects with cosmetic ingredient suppliers and pharmaceutical companies for specific product validation and claim substantiation. Includes partnership agreements with Exsymol Monaco and Mibelle Biochemistry.
Go-to-market motion3 records
Distribution channels1 record
Marketing channels5 records
ExAdEx-Innov product offering
Product offeringCore offering
ExAdEx-Innov develops and commercializes patented ex vivo human adipose (fat) tissue models derived from donor tissue for pharmaceutical, dermo-cosmetic, nutraceutical, and aesthetic medicine R&D. The models preserve native 3D vascularization, lymphatic networks, and extracellular matrix for up to 8 weeks in culture, enabling human-relevant preclinical testing, drug development for obesity and metabolic diseases, and claim substantiation for cosmetic ingredients.
Product overview
ExAdEx-Innov offers a portfolio centered on its patented ExAdEx technology platform for ex vivo human tissue modeling. The core offering comprises the ExAdEx Platform providing 3D donor-derived human adipose tissue models preserved with native vascular/lymphatic networks and extracellular matrix. Key products include ObAdEx (a biotherapy in preclinical development for obesity treatment) and the ExAdEx Longevity Lab (a hybrid in-silico/ex vivo platform for tissue longevity research with 24 aging endpoints). The platform serves pharmaceuticals (drug development for obesity and metabolic diseases) and dermo-cosmetics (ingredient testing and claims validation) through specialized sub-products including 3D Vascular Models, 3D Tissue Matrix Models, and 3D Fat Tissue Models, supported by assay services for vascular/lymphatic analysis, fibrosis/inflammation testing, and slimming/CELLULITE evaluation, plus 3D/4D imaging services.
Differentiator
Problem solved
Functional benefit
Brands
- ExAdEx Longevity Lab: Hybrid in-silico/ex vivo platform for tissue and metabolic longevity research integrating 24 aging-related endpoints
- ExAdEx Platform
- ObAdEx
- ObFAT-3D
Quantifiable outcome
- 3D models viable for up to 8 weeks in culture
- +2 more outcomes
Companies that use ExAdEx-Innov
Customer profileNamed customers4 records
Segments4 records
Ideal customer profiles3 records
ExAdEx-Innov technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
ExAdEx-Innov partnerships and signals
Strategic signalPartnerships
13 partnerships are on record, tiered major, supporting and core.
- Resalis TherapeuticsmajorPartnership for preclinical validation of RES-010 antisense oligonucleotide for obesity therapy. Provided human 3D adipose tissue models for miR-22 inhibition studies demonstrating mitochondrial activation and browning effects. Resalis presented results at Obesity Week 2025.
- Business France Nordics and BpifrancesupportingParticipated in Nordic Life Science Mission organized by Business France Nordics and Bpifrance. Included visits to AstraZeneca BioVentureHub, pitching to Novo Nordisk, Lundbeck, LEO Pharma, and Danish biotech ecosystem engagement.
- Mibelle Group BiochemistrymajorContributed to development of VividEYE™ product - an apple mint extract for eye care. Provided 3D vascularized donor-derived ex vivo models and advanced 3D/4D imaging analysis to support claims for dark circles and under-eye puffiness. Demonstrates cross-industry innovation capability.
- 3R-Center Tübingen for In vitro Models and Alternatives to Animal TestingsupportingPresentation at 3R LÄND Conference 2024 in Tübingen showcasing organoid models as non-animal methods (NAM) for human adipose tissue research. Engagement with academic labs, clinicians, industry and regulatory agencies committed to reduce animal experimentation.
- CNRS InnovationcoreLicense agreement with CNRS Innovation for hMADS (Human Multipotent Adipose-Derived Stem) 2D stem cell model to complement the proprietary 3D ExAdEx platform. Integrates standardized 2D screening capabilities with 3D tissue models for comprehensive research from screening to mechanistic studies.
- Exsymol MonacomajorCollaboration for innovative cosmetic research. Exsymol, a leader in active ingredients for cosmetics and nutrition for over 45 years (known for Silanols technology), partnered to test CAFEISILANE ingredient on ExAdEx fibro-inflammatory tissue models. Significant milestone demonstrating platform capability for human adipose tissue research.
- Institut de Biologie Valrose (iBV)coreAcademic research partnership with iBV at Université Côte d'Azur. Source of foundational technology and ongoing R&D collaboration. Lab team led by Christian Dani (Team Leader of Stem Cells and Differentiation). Labeled Labex Signalife by French National Research Agency.
- Institute of Molecular and Cellular Pharmacology (IPMC)majorCollaboration on ObFAT-3D project with IPMC team directed by Dr Bernard Mari and Dr Georges Vassaux. Joint research on 3D ex vivo human tissues to mimic obese adipose tissue, co-funded by IdEx Innovation Program France 2030 and ANRT CIFRE PhD program.
- Centre Hospitalier Universitaire (CHU) de NicemajorCollaboration with Digestive Surgery Department directed by Professor Antonio Iannelli. Provides clinical expertise and tissue sourcing. Research on adipose tissue and obesity, including ECO 2024 poster presentation on vascularized organoids.
- PRISM Imaging Facility (Institut de Biologie Valrose)coreCollaboration for 4D imaging analysis techniques. PRISM facility provides advanced imaging expertise for quantitative evaluation of vascular and lymphatic networks in 3D tissue models, including novel volume reconstruction techniques.
- La French Tech Côte d'AzursupportingMembership in French Tech mission and regional La French Tech Côte d'Azur association gathering entrepreneurs, startups and investors to boost development of French innovative and deeptech companies.
- Centre for Cardiovascular and Nutrition Research (C2VN), MarseillemajorCollaborative research on nanofat in regenerative medicine published in Facial Plastic Surgery & Aesthetic Medicine. Comprehensive review and consensus recommendations from expert opinions on nanofat applications.
- Université Côte d'AzurcoreAcademic research partnership including IdEx Innovation Program France 2030 funding. Multiple collaborative projects including ObFAT-3D project co-funded by university and Association Nationale de la Recherche et de la Technologie (ANRT).
Scale indicators5 records
Recent moves6 records
Expansion highlights6 records
ExAdEx-Innov competitors and assessment
Company assessmentDirect peers
- InSphero: Swiss 3D microtissue company offering organotypic tissue models for drug discovery and safety testing. Comparable as a provider of human-derived 3D tissue models to pharma and cosmetics companies for preclinical evaluation and claim substantiation.
- CN Bio: UK organ-on-chip company developing single- and multi-organ microphysiological systems for drug development. Direct peer in the organ-on-chip / human tissue model category, with overlap in pharma preclinical customers and similar NAM regulatory positioning.
- MIMETAS: Dutch organ-on-chip company providing 3D microfluidic tissue models for pharmaceutical drug discovery and toxicology. Closely comparable in offering human-relevant in vitro tissue platforms to pharma and cosmetics R&D customers, though MIMETAS is more general-purpose and significantly larger.
- Hesperos: US company building multi-organ 'human-on-a-chip' systems for preclinical drug testing without animal models. Comparable as a human-relevant NAM provider targeting pharmaceutical drug development with similar translational value proposition.
- Emulate: US-based organ-on-chip platform using its proprietary chip technology to model human organ function for pharma R&D. Directly comparable as a human-relevant preclinical tissue model provider serving similar pharmaceutical customers, with a broader organ portfolio than ExAdEx-Innov.
- TissUse: German multi-organ-on-chip company developing microphysiological systems for pharma, cosmetics, and chemical industry testing. Direct peer in the human-tissue-chip/NAM space with overlapping European customer base in pharma and dermo-cosmetics.
- Straticell: Belgian in vitro testing company offering 3D skin and mucosal tissue models for cosmetic, pharmaceutical, and chemical industry R&D. Comparable as a tissue-model-based testing services provider with similar cosmetics/derma-cosmetic customer use cases.
- MatTek: US-based provider of 3D reconstructed human tissue models (skin, ocular, airway, etc.) used by cosmetics, pharmaceutical, and chemical companies for safety and efficacy testing. Closely comparable in product category (3D human tissue models for cosmetics/pharma R&D) though focused on different tissue types.
Broad incumbents
- EpiSkin (L'Oréal): L'Oréal-owned pioneer of reconstructed human skin models for in vitro cosmetic and pharmaceutical testing. A broad incumbent in the same tissue-based testing category for cosmetics R&D, though specializing in skin (epidermis/dermis) rather than adipose tissue and serving as both potential competitor and ecosystem leader.
Regional players
- Biopredic International: French company supplying human biological tissues, primary cells, and in vitro testing services to pharma, cosmetics, and chemical industries. Regional peer with overlapping service offering (human tissue-based testing for R&D) and a similar French/European customer base, though broader in tissue scope.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
ExAdEx-Innov social profiles
Digital presenceExAdEx-Innov financial estimates
Financial estimateRevenue estimate
Valuation estimate
ExAdEx-Innov leadership team
Management profileNumber of profiles
Profiles9 records
ExAdEx-Innov funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
ExAdEx-Innov M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about ExAdEx-Innov
What does ExAdEx-Innov do?
ExAdEx-Innov develops and commercializes patented ex vivo human adipose (fat) tissue models derived from donor tissue for pharmaceutical, dermo-cosmetic, nutraceutical, and aesthetic medicine R&D. The models preserve native 3D vascularization, lymphatic networks, and extracellular matrix for up to 8 weeks in culture, enabling human-relevant preclinical testing, drug development for obesity and metabolic diseases, and claim substantiation for cosmetic ingredients.
Is ExAdEx-Innov a public or private company?
ExAdEx-Innov is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was ExAdEx-Innov founded?
ExAdEx-Innov was founded in 2022. It employs 1 to 10 people.
Where is ExAdEx-Innov based?
ExAdEx-Innov is headquartered in Nice, France, in the Europe region.
How does ExAdEx-Innov make money?
Three revenue lines are on record. R&D Services and Testing is the primary driver. The others are technology Licensing and collaborative Research/Co-development.
Who are ExAdEx-Innov's main competitors?
Direct peers on record are InSphero, CN Bio, MIMETAS, Hesperos, Emulate, TissUse, Straticell and MatTek. EpiSkin (L'Oréal) is listed as a broad incumbent. Biopredic International is listed as a regional player.
Does ExAdEx-Innov have an API?
No public API is recorded for ExAdEx-Innov.
What industry is ExAdEx-Innov in?
ExAdEx-Innov's product category is Preclinical Biotechnology Research Services. Its primary akta.pro industry code is HLAAAGAD, Organoids & Organ-on-Chip (regenerative models), with a secondary code of HLAAAIAJ, In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems). Its NAICS code is 325414 and its SIC code is 2836.